Welcome to our dedicated page for Lemaitre Vasculr SEC filings (Ticker: LMAT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for LeMaitre Vascular, Inc. (NASDAQ: LMAT), a Delaware-incorporated medical device company focused on vascular devices, implants, and services for peripheral vascular disease. Through these filings, investors can review the company’s formal disclosures on operations, financial condition, risk factors, and governance.
LeMaitre’s SEC submissions include annual reports on Form 10-K and quarterly reports on Form 10-Q, which present detailed financial statements, segment information, and discussions of risks such as competition, supplier dependence, regulatory compliance for devices and tissue products, international operations, product defects or recalls, litigation, and intellectual property protection. Current reports on Form 8-K, such as those referenced in the provided materials, disclose events like quarterly financial results, board decisions, and other material developments.
The company also uses its filings to describe capital markets activities, including the listing of its common stock on The Nasdaq Global Market under the symbol LMAT, the existence of convertible senior notes, dividend declarations, and share repurchase authorizations. These documents complement the non-GAAP metrics discussed in press releases by providing reconciliations and additional context for measures such as organic sales growth, adjusted margins, and EBITDA.
On Stock Titan, LeMaitre’s filings are updated in near real time from the SEC’s EDGAR system. AI-powered summaries help explain the key points in lengthy documents like 10-Ks and 10-Qs, highlight important changes from prior periods, and clarify the implications of 8-K disclosures. Users can also review insider-related filings such as Forms 3, 4, and 5, where available, to track transactions by directors and officers. This combination of raw filings and AI-generated insights allows readers to understand LMAT’s regulatory record and financial reporting more efficiently.
The Vanguard Group filed Amendment No. 6 to a Schedule 13G/A reporting its holdings in LeMaitre Vascular Inc. The amendment states 0% beneficial ownership and 0 shares beneficially owned as of the filing, following an internal realignment on 01/12/2026 that disaggregated certain subsidiaries' holdings.
The filing is signed by Ashley Grim, Head of Global Fund Administration, on 03/27/2026. It affirms that no single third party holds more than 5% of the class among accounts aggregated by Vanguard.
LeMaitre Vascular senior vice president Trent G. Kamke exercised stock options and sold the resulting shares. He exercised options for 2,625 shares of common stock at an exercise price of $35.48 per share, then sold 2,625 shares at $108.50 per share, leaving 6,677 shares owned directly.
LeMaitre Vascular’s President and Director David B. Roberts reported an open-market sale of 3,311.68 shares of common stock on March 11, 2026 at a weighted average price of $107.6752 per share. After this transaction, he directly holds 14,667.32 shares of the company’s common stock.
The sale was executed in multiple trades at prices ranging from $106.52 to $108.65, with the weighted average reported. Roberts has undertaken to provide detailed trade and pricing information to the company, its shareholders, or the SEC staff upon request.
LeMaitre Vascular’s Chief Financial Officer Dorian Paul LeBlanc reported routine equity compensation activity. On March 10, 2026, he exercised dividend equivalent rights into 2 shares of common stock at $0.00 per share and now holds 9.3269 dividend equivalent rights. He also holds 2,302 shares of common stock directly after these transactions.
The filing shows 96 shares of common stock were withheld at $109.20 per share to satisfy tax obligations on restricted stock units that vested from an award granted on March 10, 2025. The tax withholding is characterized as an exempt sale under Rule 16b-3(e) and does not reflect an open-market trade.
LMAT files a Form 144 to offer 2,625 shares of Common Stock for sale. The notice states the planned sale arises from a stock option exercise and is dated 03/11/2026.
The filing also records a prior sale of 1,044 shares on 02/27/2026 by Trent G. Kamke for $115,142.76.
LMAT insider sale disclosure: A Form 144 lists a reported sale of 8,464 shares of Common Stock by David B. Roberts on 02/27/2026 for $903,957.00. The filing also lists 3,312 Common shares tied to equity compensation (stock option exercises and RSUs) dated 12/02/2024.
LeMaitre Vascular director Martha Shadan reported equity-based compensation on common stock. On February 26, 2026, she acquired 476 shares of common stock at a price of $0.0000 per share as a grant or award. She also acquired 1 additional common share through the exercise of a dividend equivalent right linked one-for-one to common stock. These transactions stem from a Performance Share Unit award originally granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remaining portions scheduled to vest in equal annual installments on the grant date anniversaries over the next two years.
LeMaitre Vascular director John A. Roush reported equity awards and vesting activity, not open‑market trades. On February 26, 2026, he received a grant of 476 shares of common stock and 1 share from the exercise of dividend equivalent rights, bringing his directly held common stock to 3,942 shares. Related derivative dividend equivalent rights totaled 2.8963 following settlement linked to a Performance Share Unit (PSU) award granted on December 6, 2024, which vested one‑third when the performance condition was met, with the remainder vesting in equal annual installments over the next two years. An additional 181 shares are held indirectly by his spouse.
LeMaitre Vascular director Bridget A. Ross reported acquiring company stock through equity awards. On February 26, 2026 she received 476 shares of common stock upon partial vesting of a performance share unit award, plus 1 share released from dividend equivalent rights, bringing her direct holdings to 3,942 shares.
LeMaitre Vascular director John James O'Connor reported equity awards and related conversions, not open-market trading. On February 26, 2026 he acquired 476 shares of common stock at $0.0000 per share as a grant or award, bringing his direct common stock holdings to 62,826 shares, then to 62,827 shares after a related derivative conversion.
He also exercised 1 dividend equivalent right and converted it into 1 share of common stock, and now holds 2.8963 dividend equivalent rights. Footnotes explain these transactions relate to a Performance Share Unit award granted on December 6, 2024, which vested one-third upon satisfaction of its performance condition on February 26, 2026, with the remainder vesting in equal annual installments over the next two years.